Dina Ramadane
Stock Analyst at Bank of America Securities
(3.38)
# 2,224
Out of 4,670 analysts
25
Total ratings
60%
Success rate
16.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dina Ramadane
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Reiterated: Buy | $66 | $31.63 | +108.66% | 10 | Aug 17, 2026 | |
| PROK ProKidney | Reiterated: Sell | $1 | $1.33 | -24.81% | 3 | Aug 10, 2026 | |
| BHVN Biohaven | Reiterated: Buy | $11 | $14.64 | -24.86% | 8 | Aug 10, 2026 | |
| IMVT Immunovant | Reiterated: Buy | $32 → $45 | $41.82 | +7.60% | 2 | Aug 7, 2026 | |
| AMLX Amylyx Pharmaceuticals | Reiterated: Buy | $22 → $30 | $21.63 | +38.70% | 2 | Aug 7, 2026 |
Vera Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $66
Current: $31.63
Upside: +108.66%
ProKidney
Aug 10, 2026
Reiterated: Sell
Price Target: $1
Current: $1.33
Upside: -24.81%
Biohaven
Aug 10, 2026
Reiterated: Buy
Price Target: $11
Current: $14.64
Upside: -24.86%
Immunovant
Aug 7, 2026
Reiterated: Buy
Price Target: $32 → $45
Current: $41.82
Upside: +7.60%
Amylyx Pharmaceuticals
Aug 7, 2026
Reiterated: Buy
Price Target: $22 → $30
Current: $21.63
Upside: +38.70%